ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad

Christophe Guignabert, Frances de Man, Marc Lombès

Source: Eur Respir J, 51 (6) 1800848; 10.1183/13993003.00848-2018

Journal Issue: June

Disease area: Pulmonary vascular diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Christophe Guignabert, Frances de Man, Marc Lombès. ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad. Eur Respir J, 51 (6) 1800848; 10.1183/13993003.00848-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready? Source: Eur Respir J 2014; 44: 1404-1407 Year: 2014
When is pulmonary hypertension not pulmonary hypertension? Source: Eur Respir J 2001; 18: Suppl. 33, 522s Year: 2001
The future of treatment for pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018
The future of treatment for pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014
The future of treatment for pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017
The future of treatment for pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012
Is there an obesity paradox in pulmonary arterial hypertension? Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017
Improving survival in pulmonary arterial hypertension Source: Eur Respir J 2005; 25: 218-220 Year: 2005
Apelin improves cardiac output in patients with pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
CC6 Is it truly pulmonary arterial hypertension? Source: Milan 2017 - Educational material Year: 2017
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011
Challenging the concept of adding more drugs in pulmonary arterial hypertension Source: Eur Respir J, 50 (3) 1701527; 10.1183/13993003.01527-2017 Year: 2017
Dipyridamole as adjuvant therapy in patients with pulmonary arterial hypertension. A pilot study Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007
Optimal management of severe pulmonary arterial hypertension Source: Eur Respir Rev 2011; 20: 254-261 Year: 2011
Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass? Source: Eur Respir J 2014; 43: 1556-1559 Year: 2014
The role of combination therapy in managing pulmonary arterial hypertension Source: Eur Respir Rev 2014; 23: 469-475 Year: 2014
Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated Source: Eur Respir J, 57 (1) 2004258; 10.1183/13993003.04258-2020 Year: 2021
Combination therapy for pulmonary arterial hypertension: still more questions than answers Source: Eur Respir J 2004; 24: 339-340 Year: 2004
Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension Source: Eur Respir J 2010; 36: 1483-1485 Year: 2010